Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine Adjunctive Treatment in Schizophrenia
2023-508433-14-00Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Valbenazine + background antipsychotic with Placebo + background antipsychotic (2 arms). Primary endpoint: Change in PANSS total score from baseline to Week 10. Started Mar 2024; status: completed.
02
Drugs
valbenazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2023-508433-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508433-14-00.